Meso-ORIGINS

• Research type

  Research Study

• Full title

  Meso-ORIGINS: Mesothelioma Observational study of RIsk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Sub-study

• IRAS ID

  291818

• Contact name

  Alexandrea MacPherson

• Contact email

  alexandrea.macpherson@glasgow.ac.uk

• Sponsor organisation

  NHS Greater Glasgow & Clyde

• ISRCTN Number

  ISRCTN22929761

• Duration of Study in the UK

  5 years, 5 months, 31 days

• Research summary

  Malignant pleural mesothelioma (MPM) is an incurable cancer of the lining of the lung, which is strongly associated with prior asbestos exposure. MPM typical develops after decades of asbestosdriven benign pleural inflammation and it is not known what triggers the evolution from benign inflammation to MPM, or how best to treat the cancer to reverse or halt these processes.

  Meso-ORIGINS forms the prospective tissue collection element of the PREDICT-Meso International Accelerator Network funded by CRUK/AIRC/AECC. Our aim is to generate a large prospective cohort
  of asbestos-exposed patients with benign initial biopsies that we can retrieve and then match to any subsequent samples acquired at mesothelioma evolution. These samples will be used in downstream
  pre-clinical work packages to define the biology driving mesothelioma evolution, define new drug targets and validate these in a suite of pre-clinical models generated using the same material. By the end of the 5-year program we aim to have drug-target combinations ready for human trials.

  Meso-ORIGINS includes 2 arms, with Arm A recruiting patients with initial benign biopsies and includes baseline collection of blood and breath (+/-MRI depending on site capabilities) for risk profiling, and collection of additional research biopsies in some patients during the 2-year follow up -this data will help us design future studies of early intervention in high-risk patients. Arm B will recruit patients with suspected mesothelioma prior to thoracoscopic biopsy), allowing multi-region pleural biopsies for genomic heterogeneity analyses. The latter is particular important in mesothelioma because multiple tumours can exist in different areas of the pleural space and these
  may evolve at different rates and/or respond in different ways to treatment.

• REC name

  West of Scotland REC 1

• REC reference

  21/WS/0120

• Date of REC Opinion

  11 Nov 2021

• REC opinion

  Further Information Favourable Opinion